Authority on Rheumatology Practice Management and Care Pathways Joins CrossBridge Advisory Board - CrossBridge
15621
post-template-default,single,single-post,postid-15621,single-format-standard,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

Authority on Rheumatology Practice Management and Care Pathways Joins CrossBridge Advisory Board

Authority on Rheumatology Practice Management and Care Pathways Joins CrossBridge Advisory Board

Wayne, PA, January 14, 2020 – Herbert Baraf, MD, FACP, MACR, a nationally recognized authority on issues of rheumatology practice management, has joined the Advisory Board of the early stage health technology company CrossBridge.

Dr. Baraf is a senior member and managing partner of Arthritis and Rheumatism Associates (ARA), the largest private practice rheumatology group in the U. S.  He founded The Center for Rheumatology and Bone Research, ARA’s research division, and has been principal investigator on over 350 clinical trials, studying new treatments for rheumatic disorders. He is a Clinical Professor of Medicine at George Washington University School of Medicine and Clinical Associate Professor of Medicine at the University of Maryland School of Medicine.

In announcing the appointment, Bill Conlan, the Crossbridge CEO, said, “The wisdom of Dr. Baraf and that of our other Advisory Board member, Dr. Jeff Curtis, is greatly welcomed as we complete the development of our SaaS platform aimed at stimulating collaboration between specialty physicians and payers in order to bring about better outcomes at lower cost in complex, chronic diseases.”

About CrossBridge

CrossBridge is an early-stage healthcare technology company, specializing in Software as a Service (SaaS) solutions that enable payers and healthcare providers to strive collaboratively for the best outcomes at the lowest cost for chronic diseases – all while advancing the transition from fee-for-service to Value Based Payments (VBP).

No Comments

Post A Comment